CLOs on the Move

Capital Technologies

www.edbosarge.com

 
Capital Technologies, Inc., doing business as The Bosarge Family Office, supports the administration, management, investment and philanthropy of the Bosarge family. The Bosarge Family Foundation was created in 2010 and directs philanthropic support for a number of artistic, cultural, and historical institutions as well as educational, medical and environmental organizations. A devoted and energetic philanthropist, Dr. Bosarge`s activities cover a broad and diverse spectrum from supporting the renovation and preservation of historical buildings and landmarks, to constructing sustainable community improvements, and advancing local art and music programs. As a proud American, Dr. Bosarge provided the initial support and funding of ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.edbosarge.com
  • 3 Greenway Plaza Suite 1000
    Houston, TX USA 77046
  • Phone: 713.626.1919

Executives

Name Title Contact Details

Similar Companies

GRMC Lending

GRMC Lending is a mortgage lending and financial services company that blends technology and human touch for a more convenient and personal digital home buying experience.

Environmental Services Inc

Environmental Services Inc is a Wellford, SC-based company in the Business Services sector.

enGene

At enGene, we are at the vanguard of a new era in genetic medicine: Our novel Dually Derivatized Oligochitosan® (DDX) gene delivery platform is designed to enable localized delivery of multiple gene cargos, including RNA and DNA, directly to mucosal tissues and other organs — potentially overcoming the limitations of viral-based gene therapies and advancing gene therapy beyond rare genetic diseases into the mainstream of clinical practice. Our breakthrough Dually Derivatized Oligochitosan® (DDX) platform opens possibilities for streamlining the use of genetic medicines in the treatment of serious diseases, especially diseases afflicting mucosal tissues. Our lead product candidate, EG-70 (detalimogene voraplasmid), is a non-viral immunotherapy in development to treat non-muscle invasive bladder cancer (NMIBC), a disease with a significant patient burden, high clinical needs, and massive healthcare system economic impact. Based on its preliminary efficacy and safety profile and ease of administration by urologists, EG-70, which is currently in a pivotal trial, can potentially benefit patients across a wide variety of clinical settings. As enGeneers, we are boldly focused on patients needs. We are a team of passionate experts with extensive experience in drug development and commercialization across oncology, respiratory, and several other therapeutic areas. Nasdaq: ENGN

Creative Solutions Group

Creative Solutions Group is a Clawson, MI-based company in the Business Services sector.